Legal & General Group
SPRB

Legal & General Group’s Spruce Biosciences SPRB Stock Holding History

Legal & General Group’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$1K – 3498
2022
Q2 		$1K Hold
10
– – ﹤0.01% 3507
2022
Q1 		$2K Hold
10
– – ﹤0.01% 3554
2021
Q4 		$3K Hold
10
– – ﹤0.01% 3565
2021
Q3 		$5K Hold
10
– – ﹤0.01% 3480
2021
Q2 		$9K Buy
10
+1
+11% +$1.07K ﹤0.01% 3433
2021
Q1 		$12K Hold
9
– – ﹤0.01% 3332
2020
Q4 		$17K Buy
+9
New +$14.9K ﹤0.01% 3163

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's SPRB Position: Q3 2022 in Review

Legal & General Group sold out of Spruce Biosciences (SPRB) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

Legal & General Group first reported a position in SPRB in Q4 2020 and held it in 7 quarters. The position peaked at $17K in Q4 2020. 35 funds tracked by Wall St. Rank hold SPRB as of Q3 2022.

  • Legal & General Group reported no remaining Spruce Biosciences position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 10 Spruce Biosciences shares in Q3 2022, an estimated $1K.
  • Legal & General Group first reported a position in Spruce Biosciences in Q4 2020 and held it in 7 quarters.
  • Legal & General Group's Spruce Biosciences position peaked at $17K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.